Vesalius Biocapital offers venture capital
to young European innovative life science companies

logo
News News
Thursday, April 12, 2018
Promethera Biosciences Presents Novel Data on HepaStem’s Ability to Reduce Key Disease Parameters in Advanced Stage NASH in vivo Model Poster Presentation at EASL 2018 Builds on Previous Data Confirming HepaStem’s Therapeutic Potential Across Different St
Thursday, April 12, 2018
The LiMAx® liver capacity test is now commercially available in Germany, Austria and the UK
Wednesday, April 11, 2018
Clinical-grade human liver mesenchymal stem cells reduce NAS score and fibrosis progression in advanced stage NASH pre-clinical model through immunomodulation
Tuesday, April 10, 2018
Promethera Biosciences Presents Novel Data on HepaStem’s Ability to Reduce Key Disease Parameters in Advanced Stage NASH in vivo Model
Tuesday, April 10, 2018
Promethera Biosciences Raised Additional EUR 9.3 Million to Advance a Broad Product Pipeline in Severe Liver Diseases Funding Used to Advance Clinical Pipeline and Strengthen Product Portfolio
Thursday, April 5, 2018
Promethera Biosciences Acquires Baliopharm AG to Strengthen its Therapeutic Strategy in NASH With a Unique Tumor Necrosis Factor Receptor 1 (TNF-R1) Antibody Drug Candidates
Wednesday, April 4, 2018
Promethera Biosciences Announces Updates to its Board of Directors Charles L. Dimmler, III elected as new Chairman of the Board
Wednesday, March 14, 2018
Genomic Vision Extends its Collaboration with Quest Diagnostics in Spinal Muscular Atrophy (SMA)